Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery

Summary

This is a prospective randomized clinical trial designed to determine the effect of intraoperative dexmedetomidine administration on renal function after coronary artery bypass graft surgery.

Timeline

Start

2024-04-03

Primary completion

2024-07

Completion

2024-10

Outcome

Missed primary endpoint

paper Intraoperative administration of dexmedetodine during CABG surgery at a dose of 0.5 µg/kg/h without a loading dose does not lead to a decrease in the intensity of the inflammatory response after surgery. PMID 40428745 ↗

Publications

• Zdravkovic R, Vickovic S, Preveden M, Drobnjak V, Lukic-Sarkanovic M, Miljevic IB, Tatic M, Tubic T, Videnovic N, Mladenovic N, Komazec N, Dracina N, Jerkovic M, Djokovic A, Jakovljevic A, Kostic A, Mehmedi E, Redzek A. Effect of Continuous Intraoperative Dexmedetomidine on Interleukin-6 and Other Inflammatory Markers After Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial. Medicina (Kaunas). 2025 Apr 24;61(5):787. doi: 10.3390/medicina61050787.

Drugs

Indications